AU2004206187A1 - Method for inhibition of necrosis induced by neurotrophin - Google Patents
Method for inhibition of necrosis induced by neurotrophin Download PDFInfo
- Publication number
- AU2004206187A1 AU2004206187A1 AU2004206187A AU2004206187A AU2004206187A1 AU 2004206187 A1 AU2004206187 A1 AU 2004206187A1 AU 2004206187 A AU2004206187 A AU 2004206187A AU 2004206187 A AU2004206187 A AU 2004206187A AU 2004206187 A1 AU2004206187 A1 AU 2004206187A1
- Authority
- AU
- Australia
- Prior art keywords
- neurotrophin
- bdnf
- neuronal death
- prevention
- induced neuronal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0003765 | 2003-01-20 | ||
KR10-2003-0003765A KR100522188B1 (ko) | 2003-01-20 | 2003-01-20 | 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법 |
PCT/KR2004/000119 WO2004064844A1 (en) | 2003-01-20 | 2004-01-20 | Method for inhibition of necrosis induced by neurotrophin |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2004206187A1 true AU2004206187A1 (en) | 2004-08-05 |
Family
ID=36081148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004206187A Abandoned AU2004206187A1 (en) | 2003-01-20 | 2004-01-20 | Method for inhibition of necrosis induced by neurotrophin |
Country Status (8)
Country | Link |
---|---|
US (1) | US7608585B2 (de) |
EP (1) | EP1592429A4 (de) |
JP (1) | JP2006515370A (de) |
KR (1) | KR100522188B1 (de) |
CN (1) | CN1738627A (de) |
AU (1) | AU2004206187A1 (de) |
CA (1) | CA2518888A1 (de) |
WO (1) | WO2004064844A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241622B2 (en) | 2001-07-13 | 2012-08-14 | University Of Iowa Research Foundation | Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
EP1551793B1 (de) * | 2002-06-19 | 2016-01-20 | AmKor Pharma, Inc. | Tetrafluorbenzylderivate und diese enthaltende pharmazeutische zusammensetzung zur prävention und behandlung akuter und chronischer neurodegenerativer erkrankungen des zentralen nervensystems |
WO2006126825A1 (en) * | 2005-05-23 | 2006-11-30 | Choongwae Pharma Corporation | Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection |
JP5006311B2 (ja) * | 2005-05-25 | 2012-08-22 | チョンワエ ファーマ コーポレーション | 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法 |
JP5208369B2 (ja) * | 2005-08-24 | 2013-06-12 | ニューロテック ファーマシューティカルズ カンパニー リミテッド | 神経細胞の死滅または神経機能の障害を治療するための薬学製剤及び併用療法 |
US20070265350A1 (en) | 2005-12-30 | 2007-11-15 | University Of Iowa Research Foundation | Method of identifying compounds useful to treat neuronal degenerative diseases |
WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
KR100852962B1 (ko) * | 2007-11-12 | 2008-08-20 | 주식회사 뉴로테크 | 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법 |
KR101204108B1 (ko) * | 2009-02-09 | 2012-11-22 | 주식회사 지엔티파마 | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 |
AU2010235334A1 (en) * | 2009-04-06 | 2011-11-24 | Neurotech Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treating or preventing burn injuries |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
CA3016985C (en) | 2016-03-07 | 2023-07-04 | University Of Iowa Research Foundation | Aav-mediated expression using a synthetic promoter and enhancer |
KR20200088856A (ko) * | 2017-11-15 | 2020-07-23 | 벤더르빌트 유니버시티 | 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물 |
CN110257392A (zh) * | 2019-06-28 | 2019-09-20 | 西安医学院 | 转录后水平低氧调控基因、应用及其调控方法 |
BR112022018136A2 (pt) * | 2020-03-11 | 2022-10-25 | Gnt Pharma Co Ltd | Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
AU1926595A (en) | 1994-02-22 | 1995-09-04 | Syntex-Synergen Neuroscience Joint Venture, The | Pharmaceutical formulations of ciliary neurotrophic factor |
CN1267408C (zh) * | 2000-04-19 | 2006-08-02 | 纽若泰克有限公司 | 预防中枢神经系统急慢性损伤中神经变性的化合物,组合物和方法 |
-
2003
- 2003-01-20 KR KR10-2003-0003765A patent/KR100522188B1/ko not_active IP Right Cessation
-
2004
- 2004-01-20 CN CNA2004800024852A patent/CN1738627A/zh active Pending
- 2004-01-20 WO PCT/KR2004/000119 patent/WO2004064844A1/en active Application Filing
- 2004-01-20 AU AU2004206187A patent/AU2004206187A1/en not_active Abandoned
- 2004-01-20 US US10/542,936 patent/US7608585B2/en active Active
- 2004-01-20 EP EP04703527A patent/EP1592429A4/de not_active Withdrawn
- 2004-01-20 CA CA002518888A patent/CA2518888A1/en not_active Abandoned
- 2004-01-20 JP JP2006500641A patent/JP2006515370A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR100522188B1 (ko) | 2005-10-18 |
US7608585B2 (en) | 2009-10-27 |
CA2518888A1 (en) | 2004-08-05 |
WO2004064844A9 (en) | 2005-08-25 |
CN1738627A (zh) | 2006-02-22 |
JP2006515370A (ja) | 2006-05-25 |
EP1592429A1 (de) | 2005-11-09 |
WO2004064844A1 (en) | 2004-08-05 |
KR20040066639A (ko) | 2004-07-27 |
EP1592429A4 (de) | 2007-01-10 |
US20060135600A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7608585B2 (en) | Compositions for inhibition of necrosis induced by a neurotrophin | |
Bockaert et al. | mTOR in brain physiology and pathologies | |
Saavedra et al. | Driving GDNF expression: the green and the red traffic lights | |
Mennerick et al. | Neural activity and survival in the developing nervous system | |
Escames et al. | The role of mitochondria in brain aging and the effects of melatonin | |
Jiao et al. | Neuroprotective effect of astrocyte-derived IL-33 in neonatal hypoxic-ischemic brain injury | |
Beghi et al. | The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure | |
Rahi et al. | Understanding abnormal SMO-SHH signaling in autism spectrum disorder: potential drug target and therapeutic goals | |
US20150265554A1 (en) | Treatment of MeCP-2 Associated Disorders | |
Bai et al. | Attenuation of Pb-induced Aβ generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol | |
US20190125830A1 (en) | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration | |
JP2006515370A6 (ja) | 神経細胞死滅を治療するための方法及び組成物 | |
Prajapati et al. | The role of Smo-Shh/Gli signaling activation in the prevention of neurological and ageing disorders | |
Lv et al. | ATP-sensitive potassium channels: A double-edged sword in neurodegenerative diseases | |
Ding et al. | Edaravone attenuates neuronal apoptosis in hippocampus of rat traumatic brain injury model via activation of BDNF/TrkB signaling pathway | |
Iwata et al. | Treatment with GDF15, a TGFβ superfamily protein, induces protective effect on retinal ganglion cells | |
Ovcjak et al. | Ryanodine receptor inhibitor dantrolene reduces hypoxic-ischemic brain injury in neonatal mice | |
Firozan et al. | Estradiol increases expression of the brain-derived neurotrophic factor after acute administration of ethanol in the neonatal rat cerebellum | |
WO2003082216A2 (en) | Neuroprotectant methods, compositions, and screening methods thereof | |
Wang et al. | TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury | |
Li et al. | Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade | |
Nilius et al. | Are brain TRPs viable targets for curing neurodegenerative disorders and improving mental health? | |
Taguchi et al. | Minocycline alleviates cluster formation of activated microglia and age-dependent dopaminergic cell death in the substantia nigra of zitter mutant rat | |
Volsko et al. | Neuroprotective Agents: An Overview on the General Modes of Action | |
Wong et al. | Neuroimmunodegeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-APPLICANT FROM NEUROTECH CO., LTD TO NEUROTECH PHARMACEUTICALS CO., LTD. |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |